Li Yanan, Zhu Xinglong, Li Li, Bao Chunjuan, Liu Qin, Zhang Ning, He Ziyan, Ji Yi, Bao Ji
Department of Pediatric Surgery, Division of Oncology, West China Hospital of Sichuan University, 37# Guo-Xue-Xiang, Chengdu, 610041, China.
Med-X Center for Informatics, Sichuan University, Chengdu, 610041, China.
J Biol Eng. 2024 Mar 14;18(1):21. doi: 10.1186/s13036-024-00417-4.
Kaposiform hemangioendothelioma (KHE) is a rare intermediate vascular tumor with unclear pathogenesis. Recently, three dimensional (3D) cell spheroids and organoids have played an indispensable role in the study of many diseases, such as infantile hemangioma and non-involuting congenital hemangiomas. However, few research on KHE are based on the 3D model. This study aims to evaluate the 3D superiority, the similarity with KHE and the ability of drug evaluation of EOMA spheroids as an in vitro 3D KHE model.
After two days, relatively uniform morphology and high viability of EOMA spheroids were generated by the rotating cell culture system (RCCS). Through transcriptome analysis, compared with 2D EOMA cells, focal adhesion-related genes such as Itgb4, Flt1, VEGFC, TNXB, LAMA3, VWF, and VEGFD were upregulated in EOMA spheroids. Meanwhile, the EOMA spheroids injected into the subcutaneous showed more obvious KMP than 2D EOMA cells. Furthermore, EOMA spheroids possessed the similar characteristics to the KHE tissues and subcutaneous tumors, such as diagnostic markers (CD31 and LYVE-1), cell proliferation (Ki67), hypoxia (HIF-1α) and cell adhesion (E-cadherin and N-cadherin). Based on the EOMA spheroid model, we discovered that sirolimus, the first-line drug for treating KHE, could inhibit EOMA cell proliferation and downregulate the VEGFC expression. Through the extra addition of VEGFC, the effect of sirolimus on EOMA spheroid could be weakened.
With a high degree of similarity of the KHE, 3D EOMA spheroids generated by the RCCS can be used as a in vitro model for basic researches of KHE, generating subcutaneous tumors and drug screening.
卡波西样血管内皮瘤(KHE)是一种罕见的中间型血管肿瘤,其发病机制尚不清楚。近年来,三维(3D)细胞球体和类器官在许多疾病的研究中发挥了不可或缺的作用,如婴儿血管瘤和非消退性先天性血管瘤。然而,基于3D模型对KHE的研究较少。本研究旨在评估作为体外3D KHE模型的EOMA球体的3D优势、与KHE的相似性以及药物评估能力。
两天后,旋转细胞培养系统(RCCS)生成了形态相对均匀且活力较高的EOMA球体。通过转录组分析,与二维EOMA细胞相比,EOMA球体中整合素β4(Itgb4)、血管内皮生长因子受体1(Flt1)、血管内皮生长因子C(VEGFC)、腱生蛋白X(TNXB)、层粘连蛋白α3(LAMA3)、血管性血友病因子(VWF)和血管内皮生长因子D(VEGFD)等黏着斑相关基因上调。同时,注射到皮下的EOMA球体比二维EOMA细胞表现出更明显的卡波西样血管内皮瘤增殖(KMP)。此外,EOMA球体具有与KHE组织和皮下肿瘤相似的特征,如诊断标志物(CD31和淋巴管内皮透明质酸受体1(LYVE-1))、细胞增殖(Ki67)、缺氧(缺氧诱导因子-1α(HIF-1α))和细胞黏附(E-钙黏蛋白和N-钙黏蛋白)。基于EOMA球体模型,我们发现治疗KHE的一线药物西罗莫司可抑制EOMA细胞增殖并下调VEGFC表达。通过额外添加VEGFC,西罗莫司对EOMA球体的作用可被削弱。
由RCCS生成的3D EOMA球体与KHE具有高度相似性,可作为KHE基础研究、皮下肿瘤生成和药物筛选的体外模型。